Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms VERITAS
- Sponsors AbbVie
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2016 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
- 09 Nov 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2018.